OncoMatch/Clinical Trials/NCT05595590
Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Is NCT05595590 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab for head and neck cancer.
Treatment: Tislelizumab — The purpose of this study is to determine the efficacy and safety of pulsed radiotherapy given concomitantly with Tislelizumab and as maintenance therapy in participants with locoregionally recurrent head and neck squamous cell carcinoma ( HNSCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Must have received: radical therapy (surgery ± chemoradiotherapy or radical chemoradiotherapy)
Previous radical therapy (surgery ± chemoradiotherapy or radical chemoradiotherapy) and the records of radiation fields and dosage of previous treatment can be obtained.
Cannot have received: reradiotherapy
had received reradiotherapy within 1 month prior to entering the study
Cannot have received: systemic immunosuppressive drugs
Exception: prophylactic antibiotic therapy allowed
Receiving systemic immunosuppressive drugs within 2 weeks prior to commencing study treatment, or anticipating needing systemic immunosuppressive drugs during study treatment
Cannot have received: systemic immune-stimulating agents (interferon, interleukin-2)
having received systemic immune-stimulating agents (including but not limited to interferon or interleukin-2 [IL-2]) within 4 weeks prior to study treatment initiation or remaining within 5 half-lives (whichever is longer)
Cannot have received: immunotherapy (PD-1 antibody, PD-L1 antibody, CTLA-4 antibody)
Immunotherapy such as PD-1/L1 antibody or CTLA-4 antibody within 4 weeks before enrollment
Cannot have received: chemotherapy
Chemotherapy or targeted therapy within 4 weeks prior to enrollment
Cannot have received: targeted therapy
Chemotherapy or targeted therapy within 4 weeks prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify